1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations
(
- Contribution to journal › Article
- 2016
-
Mark
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
(
- Contribution to journal › Article
- 2013
-
Mark
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
(
- Contribution to journal › Article
- 2012
-
Mark
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
(
- Contribution to journal › Article
-
Mark
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
(
- Contribution to journal › Article
- 2010
-
Mark
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
(
- Contribution to journal › Article
-
Mark
Low expression of CysLT(1)R and high expression of CysLT(2)R mediate good prognosis in colorectal cancer
(
- Contribution to journal › Article
- 2009
-
Mark
Interim analysis of epidermal-growth factor receptor (EGFR) expression in a single-arm, phase II, first-line study (20060314) of panitumumab with FOLFIRI in the management of metastatic colorectal cancer (mCRC)
2009) 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology In EJC Supplements 7(2). p.343-344(
- Contribution to journal › Published meeting abstract
-
Mark
Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study.
(
- Contribution to journal › Article